A US Food and Drug Administration advisory panel is recommending approval of Pfizer’s abuse-resistant opioid painkiller ALO-02.
News
BMS hooks up again with MD Anderson Cancer Centre
Bristol-Myers Squibb and The University of Texas MD Anderson Cancer Center have formed a new clinical research collaboration to assess potential new uses of immunotherapies Opdivo and Yervoy to treat early- and advanced-stage lung cancer patients.
Novartis plans head-to-head trial for Cosentyx and Humira
Novartis and Sandoz are to present new analyses indicating that their biologic Cosentyx could lead to higher responses than AbbVie’s anti-inflammatory super-blockbuster Humira in improving the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.
Researchers test bubbly drinks for boosting cancer treatment
UK researchers are exploring a novel approach to boosting existing cancer treatment, assessing whether oxygenated drinks could increase its potency.
SkyePharma buys access to abuse deterrent drug delivery tech
Skyepharma has bought itself access Lucideon’s abuse-deterrent drug delivery technology to use in the development of a new formulation of an undisclosed opioid.
FDA panel backs Teva’s new abuse-deterrent opioid
US Food and Drug Administration advisors have backed approval of Teva’s abuse-deterrent opioid Vantrela ER.
AIDS charity gears up to challenge NHS England in court
The National AIDS Trust (NAT) is gearing up to fight in court a decision by NHS England to remove prophylactic HIV treatment PrEP from the official NHS commissioning process.
Sanofi/Regeneron’s dupilumab hits targets in dermatitis trial
Sanofi and Regeneron’s experimental therapy dupilumab has hit primary and secondary targets in a late-stage trial assessing its effectiveness in patients with poorly controlled atopic dermatitis.
UK launch for first hereditary factor X deficiency treatment
The first and only treatment licensed specifically for the rare bleeding disorder hereditary factor X deficiency has now been launched across the UK.
Trial shows high response rates for Merck’s Keytruda
An analysis of data from a Phase II study of Merck & Co’s immunotherapy Keytruda has demonstrated high response rates in heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Health sector will suffer from Brexit, warns Economist report
Britain’s exit from the European Union will lead to cuts in NHS spending and put close to 10,000 doctors and 19,000 nurses at risk, concludes a new report by the Economist Intelligence Unit.
NHS drugs bill fattened by corporate profiteering, investigation claims
The National Health Service’s annual drugs bill is being inflated by some £262 million through “extortionate” price hikes on a group of medicines controlled by a handful of millionaire businessmen, claims a report in The Times.
Merck links with Array, Pierre Fabre to test cancer combo
Germany’s Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer.
Data backs first-line use of Roche’s Tecentriq
Roche’ bladder cancer drug Tecentriq shrank tumours in 24 percent of patients previously untreated for the disease, raising hopes that it might be approved in the first-line setting.
J&J’s Darzalex improves outcomes in multiple myeloma trial
Adding Johnson & Johnson’s Darzalex to the standard regimen of Takeda’s Velcade and dexamethasone significantly improved outcomes for patients with recurrent or refractory multiple myeloma, show findings of a late-stage trial.
